Quality of life improved in ragweed allergic patients treated with captisol-enabled® budesonide+azelastine nasal solution (CDX-313) compared to placebo and reference treatment (As + RA) using an environmental exposure chamber-specific rhinoconjunctivitis quality of life questionnaire (EEC-QOL)

The requested reference [a69904ae726f6819ffe0d5cee51ce5e92e4068de] no longer exists in our database. It has been replaced by the current reference: [61d3bcdd476f4b8bb71ca9c21738b0f937975245]

Authors
Category Primary study
JournalAnnals of Allergy, Asthma and Immunology
Year 2009
This article has no abstract
Epistemonikos ID: e02d85827e10d00fa32ec35efdf3cc81a2f6088f
First added on: Mar 01, 2025